Doctors Without Borders/Médecins Sans Frontières (MSF) TB Symposium

Welcoming Address: Howard Milstein, JD MBA

Trustee Emeritus and Presidential Councilor, Cornell University

No Time to Wait: Overcoming Gaps in TB Research
and Development (pdf)

Taped Address: Anthony S. Fauci, MD

Director of the National Institute of Allergy and Infectious Diseases (NIAID)

Opening Address Transcript - Dr. Fauci (pdf)

Opening remarks: Tido von Schoen-Angerer, MD

Director, Campaign for Access to Essential Medicines, Médecins Sans Frontières

Welcome Address TB Symposium Dr. Tido von Schoen-Angerer (pdf)

Global TB Control: Achievements, Challenges, and the Need for Better Tools

Mario Raviglione, MD
Director, Stop Tuberculosis Department, World Health Organization

Mario Raviglione - WHO - Global TB Control in 2007 (pdf)

Drugs Ð Where We are Today, the Vision for Tomorrow

Maria Freire, PhD
President and CEO, Global Alliance for TB Drug Development

Maria Freire - TB Alliance - TB Drugs (pdf)

Insurmountable Challenges in TB Treatment

Francis Varaine, MD
Chairman, TB Working Group, Médecins Sans Frontières

Francis Varaine - MSF-TB Working Group (pdf)

Limitations of the Current Pipeline:
Lessons from Persisters and Persister Drug PZA

Ying Zhang, MD, PhD
Professor of Molecular Microbiology and Immunology,
Johns Hopkins University Bloomberg School of Public Health

Ying Zhang - Limitations of the Current Pipeline (pdf)

Accelerating TB Drug Discovery

Ken Duncan, PhD
Senior Program Officer, Bill and Melinda Gates Foundation

Ken Duncan - Gates Foundation (pdf)

Bridging the Gaps in TB Drug Discovery Ð Creating International Medicinal Chemistry Resource Centers

Alan Kozikowski, PhD
Professor of Medicinal Chemistry and Pharmacology, College of Pharmacy,
University of Illinois at Chicago

Scott Franzblau, PhD
Director, Institute for Tuberculosis Research, University of Illinois at Chicago

Scott Franzblau Chemistry - limited TB DD (pdf)

Alan Kozikowski - Bridging the Gaps (pdf)

Managing Intellectual Property in Academia to Ensure
Future Access to Products

Amy Kapczynski, JD
ISP Samuelson Fellow/EPH Post-Doctoral Fellow, Yale Law School

Amy Kapczynski - Yale Law - Managing Intellectual Property (pdf)

Evaluating New Drugs Through Clinical Trials:
Current Capacity and Future Needs

Neil Schluger, MD
Chairman of the Steering Committee, Tuberculosis Trials Consortium (TBTC),
Associate Professor of Medicine and Public Health Chief, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University

Neil Schluger - TBTC (pdf)

Conforming to GCP/GLP Standards in Resource-Poor Settings:
Can We Meet the Challenge?

Christian Leinhardt, MD
Director of Research, International Union Against Tuberculosis and Lung Diseases (IUATLD) and L'Institut de recherche pour le développement (IRD)

Christian Lienhardt (pdf)

Shortening the Clinical Development of Drugs for Tuberculosis

Leonard Sacks, MD
Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Leonard Sacks - FDA - Shortening Clinical Development (pdf)

How TMC207 Progressed through Development

Karel De Beule, PharMD, MBA
Compound Development Team Leader Tibotec

Karel DeBeule - Tibotec - Development of TMC207 (pdf)

Lessons from the Past - Ways to Speed Up Clinical Trials

William Burman, MD
Director of the Infectious Diseases Clinic and
Study ChairÊTuberculosis Trials Consortium, Denver Public Health

William Burman - Denver Public Health (pdf)

R&D: The Gap between Needs & Realities

Mark Harrington
Executive Director, Treatment Action Group

Mark Harrington - TAG - TB R&D The Gap (pdf)

Strategy for a Treaty on Research and Development

James Love, MPA
Director, Consumer Project on Technology

Jamie Love - CPT - Strategy for a Treaty (pdf)

The Intergovernmental Working Group on Public Health, Innovation and Intellectual Property

Dermot Maher
STOP Tuberculosis Department, World Health Organization

Dermot Maher - WHO - Intergovernmental Working Group (pdf)

Day 1 - Presentations